Galectin Therapeutics (GALT) Live Share Price, Invest From India

Galectin Therapeutics Stock Performance

as on October 26, 2026 at 2:16 pm IST

Day's Low
Day's High
$3.16
Day's Price Range
$3.32
$3.19
0.94%
Downside
4.08%
Upside
52 Week's Low
52 Week's High
$2.03
52-Week Price Range
$7.13
$3.19
36.52%
Downside
123.51%
Upside

Galectin Therapeutics share price movements today

Previous Close: $3.38
Open: $3.32
Volume: 672.2K
Market Cap: $321.7M
Day's Low - High: $3.16 - $3.32
52 Week Low - High: $2.03 - $7.13

Galectin Therapeutics Historical Returns

1 Month Return: -18.21 %
3 Month Return: -8.07 %
1 Year Return: -39.01 %
3 Year Return: + 53.37 %
5 Year Return: -2.15 %

Galectin Therapeutics Stock Fundamentals & Key Indicators

Check Galectin Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$321.7M

EPS (TTM)

-0.427

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.47

Industry PE ratio

-7.96

PEG Ratio

-0.19

EBITDA

-13.8M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

21.48%

Galectin Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Galectin Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Galectin Therapeutics	Buy	$321.7M	-2.15%	-7.47	0.00%	0.00%
Moderna	Neutral	$79.9B	-42.12%	-25.08	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$132.8B	184.64%	30.25	86.04%	0.00%
Regeneron	Buy	$82.9B	35.95%	19.22	84.86%	0.46%

Stock Returns calculator for Galectin Therapeutics Stock including INR - Dollar returns

The Galectin Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Galectin Therapeutics investment value today

Current value as on today

₹65,637

Returns

-₹34,363

(-34.36%)

Returns from Galectin Therapeutics Stock

-₹39,006 (-39.01%)

Dollar Impact

₹4,643 (+4.64%)

Analyst Recommendation on Galectin Therapeutics Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Galectin Therapeutics. Average target price of $11

Galectin Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Galectin Therapeutics.

What analysts predicted

71%UPSIDE

Target Price

$11

Current Price

$3.19

Analyzed by

7 Analysts

Target

$11.00

Galectin Therapeutics target price $11, a slight upside of 71% compared to current price of $3.19. According to 7 analysts rating.

Indian Investors' Interest in Galectin Therapeutics Stock

Search interest for Galectin Therapeutics Stock has decreased by -52% in the last 30 days, reflecting a downward trend in search activity.

Time period: September 26, 2026 to October 26, 2026

Change:-52% versus previous 30 day period

Galectin Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-
Operating Income	-9	-9	-9	-11	-9	-7	-4	-4	-4	-3
EBITDA	-9	-9	-10	-11	-9	-7	-5	-6	-3	0
Interest Expense	0	0	1	1	1	1	1	1	1	2
Depreciation	0	0	0	0	0	0	0	-	0	0
Income Before Tax	-10	-9	-11	-12	-11	-9	-7	-8	-5	-9
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-10	-9	-11	-12	-11	-9	-7	-8	-5	-9
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Galectin Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Mar 2021	Mar 2022	Dec 2022	Dec 2023	Mar 2025	Mar 2026
Total Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	-	-	-	-	-	-	-
Operating Income	-16	-13	-13	-23	-30	-38	-38	-42	-20
EBITDA	-16	-13	-13	-23	-29	-37	-38	-41	-23
Interest Expense	0	0	0	0	0	1	2	5	7
Depreciation	0	0	0	0	0	0	0	0	0
Income Before Tax	-16	-13	-13	-23	-30	-38	-41	-47	-30
Income Tax Expense	-	-	-	-	-	-	-	-	-
Net Income	-16	-13	-13	-23	-30	-38	-41	-47	-30
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Galectin Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Net Income	-10	-9	-11	-12	-11	-9	-7	-8	-5	-9
Operating Cash Flow	-7	-4	-12	-8	-8	-7	-6	-3	-3	-2
Investing Cash Flow	-	-	-	-	-	-	-	-	-	-
Financing Cash Flow	10	10	10	10	10	-	12	1	0	1
Change in Cash	2	5	-2	2	1	-7	6	-2	-3	0

Galectin Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Mar 2021	Mar 2022	Dec 2022	Dec 2023	Mar 2025	Mar 2026
Net Income	-16	-13	-13	-23	-30	-38	-41	-47	-30
Operating Cash Flow	-15	-10	-10	-20	-24	-31	-32	-41	-23
Investing Cash Flow	-	-	-	-	-	-	-	-	-
Financing Cash Flow	3	15	50	0	36	10	40	31	26
Change in Cash	-12	5	39	-20	12	-21	7	-10	2

Global Institutional Holdings in Galectin Therapeutics

Check out the Institutions with significant holdings in Galectin Therapeutics.

Funds	Holdings
Vanguard	2.35%
VANGUARD INDEX FUNDS	1.90%
iShares	1.75%
Fidelity Concord Street Trust	0.53%
SPDR	0.07%

See all

Insights on Galectin Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Moderna, Inc. Common Stock has given 163.4% return, outperforming this stock by 110.0%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 648.3% return, outperforming this stock by 687.3%
NEGATIVE IMPACT
Price Dip
In the last 7 days, GALT stock has moved down by -8.7%

About Galectin Therapeutics

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Organisation	Galectin Therapeutics
Headquarters	4960 Peachtree Industrial Boulevard, Norcross, GA, 30071, US
Industry	Biotechnology
CEO	Joel Lewis

Key Management of Galectin Therapeutics

Name	Title
Mr. Jim Wilkins Ph.D.	Head of CMC & Pharmaceutical Development
Ms. Beth Knowles	Executive Assistant & Officer Manager
Dr. Khurram Jamil M.D.	Chief Medical Officer
Mr. Robert Tritt J.D.	General Counsel

FAQs

What is Galectin Therapeutics share price today?

Galectin Therapeutics share price today is $3.19 as on October 26, 2026 at 8:46 am IST at the close of the market. Galectin Therapeutics share today touched a day high of $3.32 and a low of $3.16.

What is the 52 week high and 52 week low for Galectin Therapeutics share?

Galectin Therapeutics share touched a 52 week high of $7.13 on December 17, 2025 and a 52 week low of $2.03 on May 7, 2026. Galectin Therapeutics stock price today i.e. October 26, 2026 at 8:46 am IST is closed at $3.19,which is 55.26% down from its 52 week high and 57.53% up from its 52 week low.

What is Galectin Therapeutics's market capitalisation today?

Galectin Therapeutics market capitalisation is $0.00T as on October 26, 2026 at 8:46 am IST.

How to invest in Galectin Therapeutics Stock (GALT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Galectin Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Galectin Therapeutics Stock (GALT) from India?

Indian investors can start investing in Galectin Therapeutics (GALT) shares with as little as ₹94.94000244140625 or $1 (as of October 26, 2026 at 9:40 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Galectin Therapeutics stock (as per the Rupee-Dollar exchange rate as on October 26, 2026 at 9:40 am IST). Based on Galectin Therapeutics share’s latest price of $3.19 as on October 26, 2026 at 8:46 am IST, you will get 3.1348 shares of Galectin Therapeutics. Learn more about fractional shares .

What are the returns that Galectin Therapeutics has given to Indian investors in the last 5 years?

Galectin Therapeutics stock has given -2.15% share price returns and 26.39% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?